AbbVie Inc. (ABBV)
NYSE: ABBV
· Real-Time Price · USD
190.90
-0.18 (-0.09%)
At close: Jun 16, 2025, 2:08 PM
-0.09% (1D)
| Bid | 190.9 |
| Market Cap | 337.21B |
| Revenue (ttm) | 57.37B |
| Net Income (ttm) | 4.2B |
| EPS (ttm) | 2.36 |
| PE Ratio (ttm) | 80.89 |
| Forward PE | 13.73 |
| Analyst | Buy |
| Ask | 190.92 |
| Volume | 1,645,411 |
| Avg. Volume (20D) | 7,720,980 |
| Open | 190.90 |
| Previous Close | 191.08 |
| Day's Range | 188.93 - 191.66 |
| 52-Week Range | 163.52 - 218.66 |
| Beta | 0.49 |
About ABBV
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABBV
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABBV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-5.62%
AbbVie shares are trading lower after Citigroup do...
Unlock content with
Pro Subscription
1 month ago
+3.38%
AbbVie shares are trading higher after multiple analysts raised their price targets on the stock. The company last week reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.
23 hours ago · seekingalpha.com
AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend GrowthAbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expec...
